secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0002023658-25-000107
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa
--------------------------------------------------------------------------------

- Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.
- Cash, equivalents, investments $407.6M as of Sept 30, 2025; expected to fund operations into H1 2029.
- FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV-negative R/M HNSCC.
- Phase 1b data for 750mg weekly dose of ficerafusp alfa + pembrolizumab expected at ESMO Asia 2025.
- Expanded management team: Jenna Cohen (Chief Corp Affairs), Tanya Green (Chief Dev Officer), Bill Schelman (VP).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/0002023658-25-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/bcax-20251110.htm
  HTML page:      https://secwatch.observer/filing/0002023658-25-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer